Registered Kenya · PPB

DEXPURE TABLETS

DEXRABEPRAZOLE SODIUM

What it does

Dexrabeprazole is a medication that helps reduce stomach acid production.

Commonly used for: gastroesophageal reflux disease (GERD), stomach ulcers, esophagitis (inflammation of the esophagus)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
CTD1092
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
DEXRABEPRAZOLE SODIUM
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Lazor Pharmaceuticals
Applicant / LTR
-
Country of origin
FOREIGN
Manufacturer location
14 Joy Avenue, Ajao Estate, Lagos 102214, Lagos, Nigeria

Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:54:00 · updated 2026-07-26 11:44:32

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Dexrabeprazole is a medication that helps reduce stomach acid production.

What it treats

  • gastroesophageal reflux disease (GERD)
  • stomach ulcers
  • esophagitis (inflammation of the esophagus)

How it works

It works by blocking the pumps in the stomach that produce acid, helping to heal the stomach and relieve symptoms.

Who it's for

This medicine is for adults and children who need help with conditions caused by too much stomach acid.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: dexrabeprazole

BNF-referenced

Dexrabeprazole is a proton pump inhibitor (PPI) used primarily for the treatment of gastrointestinal disorders related to excess stomach acid. It is the active enantiomer of rabeprazole and works by reducing gastric acid secretion, thus providing relief from conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers.

Indications

  • Gastroesophageal reflux disease (GERD)
  • Peptic ulcer disease
  • Zollinger-Ellison syndrome

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines.

Mechanism of action

Dexrabeprazole inhibits the hydrogen-potassium ATPase enzyme system (proton pump) at the secretory surface of the gastric parietal cells, leading to a profound and long-lasting reduction in gastric acid secretion.

Pharmacodynamics

As a PPI, dexrabeprazole effectively suppresses both basal and stimulated gastric acid secretion. The onset of action typically occurs within one hour of administration, with peak effects seen within two to four hours. The duration of acid suppression can last up to 24 hours, allowing for once-daily dosing.

Pharmacokinetics

Dexrabeprazole is rapidly absorbed after oral administration, with peak plasma concentrations occurring about one to four hours post-dose. It is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C19 and CYP3A4. The elimination half-life is approximately one hour, with metabolites excreted primarily in urine.

Contra-indications

  • Hypersensitivity to dexrabeprazole or any of its excipients
  • Severe liver impairment

Adverse effects

  • Headache
  • Dizziness
  • Nausea
  • Diarrhoea
  • Abdominal pain
  • Constipation
  • Flatulence
  • Skin rash
  • Elevated liver enzymes

Interactions

  • May reduce the absorption of drugs requiring an acidic environment for absorption
  • Increased risk of gastrointestinal infections with antibiotics
  • May interact with anticoagulants and antiplatelet agents

Precautions

  • Use with caution in patients with a history of liver disease
  • Caution in patients with a known risk of Clostridium difficile infection
  • Monitor for signs of hypomagnesemia

Pregnancy

The safety of dexrabeprazole in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether dexrabeprazole is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

  • Tablets
  • Capsules

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: dexrabeprazole

PubChem CID 9906855

Molecular formula: C18H21N3O3S

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.